Gilead Sciences (GILD) Amortizatization of Intangibles (2009 - 2026)
Gilead Sciences' (GILD) quarterly Amortizatization of Intangibles came in at $596.0 million in Q1 2026, down 0.5% YoY from $599.0 million in Q1 2025, and little changed on a QoQ basis from $597.0 million in Q4 2025.
Gilead Sciences (GILD) Amortizatization of Intangibles (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Amortizatization of Intangibles data on file, last reported at $596.0 million in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 0.5% year-over-year to $596.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 billion (changed 0.08% YoY) and the FY2025 annual result came in at $2.4 billion, changed 0.17% from the prior year.
- Amortizatization of Intangibles held at $596.0 million in Q1 2026, from $597.0 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $599.0 million in Q1 2025 to a low of $445.0 million in Q1 2022.
- A 5-year average of $558.3 million and a median of $596.0 million in 2024 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles soared 34.38% — and 2026, when it dropped 0.5%.
- Tracing GILD's Amortizatization of Intangibles over 5 years: stood at $445.0 million in 2022, then jumped by 34.16% to $597.0 million in 2023, then increased by 0.17% to $598.0 million in 2024, then dropped by 0.17% to $597.0 million in 2025, then slipped by 0.17% to $596.0 million in 2026.
- The last three Amortizatization of Intangibles figures came in at $596.0 million (Q1 2026), $597.0 million (Q4 2025), and $596.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 984.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 600.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 600.00 Mn |
| Jun 30, 2026 | 600.00 Mn |
| Mar 31, 2026 | 596.00 Mn |
| Mar 31, 2026 | 596.00 Mn |
| Dec 31, 2025 | 597.00 Mn |
| Dec 31, 2025 | 597.00 Mn |
| Sep 30, 2025 | 596.00 Mn |
| Sep 30, 2025 | 596.00 Mn |
| Jun 30, 2025 | 598.00 Mn |
| Jun 30, 2025 | 598.00 Mn |
| Mar 31, 2025 | 599.00 Mn |
| Mar 31, 2025 | 599.00 Mn |
| Dec 31, 2024 | 598.00 Mn |
| Dec 31, 2024 | 598.00 Mn |
| Sep 30, 2024 | 596.00 Mn |
| Sep 30, 2024 | 596.00 Mn |
| Jun 30, 2024 | 596.00 Mn |
| Jun 30, 2024 | 596.00 Mn |
| Mar 31, 2024 | 596.00 Mn |
| Mar 31, 2024 | 596.00 Mn |